Pharmacosmos settles legal dispute with Vifor

Pharmacosmos is now withdrawing the press release that the Danish Medicines Agency has ruled was in breach of the Danish Medicines Act. The ruling was the root of the subsequent case which competitor Vifor brought against the company in the Maritime and Commercial High Court of Denmark.

Photo: Pharmacosmos / PR

Approximately two years have passed since the conflict between the Danish company Pharmacosmos and Vifor Pharma, which is based in Switzerland, began over a phosphare study. The conflict is now solved in a settlement in the Maritime and Commercial High Court of Denmark.

Vifor Pharma, which like the Danish company produces medicines for the treatment of iron deficiency anaemia, originally brought the suit against Pharmacosmos after the Danish Medicines Agency judged a press release concerning the study's findings to be in breach of the Danish Medicines Act.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs